Pacira Pharmaceuticals Inc (PCRX)

Working capital turnover

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Revenue (ttm) US$ in thousands 638,707 621,403 618,553 613,360 627,091 646,604 609,214 577,203 541,534 491,997 489,092 436,030 429,647 421,097 408,298 435,397 421,026 393,717 372,480 353,983
Total current assets US$ in thousands 509,994 447,255 429,324 376,114 498,334 533,411 526,210 667,018 866,048 822,352 792,579 720,247 651,623 658,520 455,823 431,594 408,557 378,847 394,609 508,673
Total current liabilities US$ in thousands 97,383 93,661 108,912 98,698 147,774 131,526 133,179 305,073 521,118 225,788 228,693 232,084 253,328 86,272 70,583 80,313 107,673 95,838 83,004 58,991
Working capital turnover 1.55 1.76 1.93 2.21 1.79 1.61 1.55 1.59 1.57 0.82 0.87 0.89 1.08 0.74 1.06 1.24 1.40 1.39 1.20 0.79

December 31, 2023 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $638,707K ÷ ($509,994K – $97,383K)
= 1.55

Pacira BioSciences Inc's working capital turnover has fluctuated over the past eight quarters, ranging from a low of 1.56 in Q2 2022 to a high of 2.41 in Q1 2023. The working capital turnover ratio indicates how efficiently the company is utilizing its working capital to generate revenue. A higher ratio suggests that the company is effectively managing its working capital to generate sales, while a lower ratio may indicate inefficiencies in working capital management.

In Pacira BioSciences Inc's case, we can observe an overall increasing trend in the working capital turnover ratio from Q2 2022 to Q1 2023, indicating improved efficiency in converting working capital into sales during this period. However, the ratio declined in Q4 2023 compared to the previous quarter, which suggests that the company may have experienced challenges in optimizing its working capital efficiency in the most recent period.

Further analysis of the underlying factors contributing to these fluctuations in the working capital turnover ratio, such as changes in inventory management, accounts receivable, and accounts payable practices, would be necessary to provide a more detailed assessment of Pacira BioSciences Inc's working capital management performance.